phrykt

Armata Pharmaceuticals, Inc. (ARMP): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ARMP were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Armata Pharmaceuticals

From the latest filings

Overall: more buying than selling. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ARMP

54 funds and institutions reported ARMP shares worth $32.5M at the end of Q2 2026, about 14% of the company. The largest holder is Madison Asset Management, LLC with 5.8%.

Funds and institutions (13F) 14%Everyone else 86%

10 largest owners, by share of the company

Madison Asset Management, LLC5.8%
BlackRock, Inc.1.5%
Vanguard Capital Management LLC1.3%
Millennium Management LLC1.3%
Geode Capital Management, LLC0.7%
Dauntless Investment Group, LLC0.6%
State Street Corp0.4%
Northern Trust Corp0.2%
Vanguard Portfolio Management LLC0.2%
Edgewood Management LLC0.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Madison Asset Management, LLC2.11M5.75%$13.7MNo change
BlackRock, Inc.559,9861.53%$3.6M+761%
Vanguard Capital Management LLC487,9681.33%$3.2M+33%
Millennium Management LLC470,5001.28%$3M+82%
Geode Capital Management, LLC270,5500.74%$1.8M+136%
Dauntless Investment Group, LLC203,8910.56%$1.3M+125%
State Street Corp129,6000.35%$840K+155%
Northern Trust Corp89,7910.25%$582K+264%
Vanguard Portfolio Management LLC81,3540.22%$527KNew
Edgewood Management LLC80,0000.22%$518K-20%
Vanguard Fiduciary Trust Co79,4950.22%$515K+17%
Grey Ledge Advisors, LLC50,0000.14%$324K+67%
Renaissance Technologies LLC48,3180.13%$313K+26%
Bridgeway Capital Management, LLC44,6820.12%$290KNo change
SeaCrest Wealth Management, LLC41,5240.11%$269KNo change
Bank of New York Mellon Corp29,7490.08%$193KNew
Charles Schwab Investment Management Inc28,8570.08%$187KNew
Sixth Street Partners Management Company, L.P.28,8570.08%$187KNew
Hudson Bay Capital Management LP17,5840.05%$114KNo change
Nuveen, LLC15,9050.04%$103KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No ARMP insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ARMP short interest

Low short interest. 2.5% of ARMP shares are sold short: about 1 share in 41. Over the last 12 reports the number of shares short went up 306%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 912,610 ARMP shares were sold short, 2.5% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 93,354 shares, buying them all back would take about 9.8 trading days (days to cover).

Shares short, % of all shares

2.45%May 15Oct 302.90%

Days to cover

9.8May 15Oct 3011.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026912,6102.45%+1%93,3549.8
Oct 15, 2026899,6392.42%-7%105,3268.5
Sep 30, 2026964,1872.59%+0%160,8906.0
Sep 15, 2026963,3832.59%+9%583,2171.6
Aug 31, 2026885,2912.38%+6%101,9408.7
Aug 14, 2026834,7372.25%-3%130,0456.4
Jul 31, 2026856,3632.34%+22%171,9535.0
Jul 15, 2026704,6571.92%+60%154,7224.5
Jun 30, 2026441,1571.20%+113%302,8731.5
Jun 15, 2026206,8730.56%-1%53,5753.9
May 29, 2026209,3630.57%-7%84,4202.5
May 15, 2026225,0330.61%-2%77,2072.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Armata Pharmaceuticals company events

Armata Pharmaceuticals filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Sep 23, 2026.

  1. Sep 23, 2026AnnouncementArmata Pharmaceuticals, Inc. issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intravenously administered… Filing
  2. Sep 14, 2026AnnouncementShared information with investors. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jul 20, 2026AnnouncementShared information with investors. Filing
  5. Jul 20, 2026LeadershipThe Board of Directors of Armata Pharmaceuticals, Inc. promoted and appointed David House as the Company’s Chief Financial Officer, effective July 17, 2026. Filing
  6. Jul 13, 2026AnnouncementShared information with investors. Filing
  7. Jun 24, 2026LeadershipAmended an earlier report. Of Form 8-K, this Amendment is being filed solely to disclose the Board’s determination of Dr. Gilmer’s Board committee assignments. Filing
  8. Jun 23, 2026AnnouncementThe Company issued a press release announcing that it had received $2.5 million of additional non-dilutive award funding from the U.S. Department of Defense for the development of AP-SA02, the Company's intravenously administered Staphylococcus aureus phage product candidate, to treat complicated… Filing
  9. Jun 16, 2026VoteReported shareholder vote results. Filing
  10. May 13, 2026AgreementArmata Pharmaceuticals, Inc. announced in the press release furnished hereto as Exhibit 99.1 that, on May 12, 2026, it had entered into, as borrower, a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of… Filing
  11. May 7, 2026AnnouncementShared information with investors. Filing
  12. Apr 27, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  13. Apr 2, 2026AnnouncementArmata Pharmaceuticals, Inc. has set June 11, 2026 as the date for its 2026 annual meeting of stockholders. Filing
  14. Mar 25, 2026ResultsReleased financial results. Filing
  15. Mar 19, 2026AnnouncementShared information with investors. Filing
  16. Feb 23, 2026AnnouncementShared information with investors. Filing
  17. Jan 26, 2026AgreementArmata Pharmaceuticals, Inc. entered into amendments to four existing credit agreements, each as previously amended, with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. Filing
  18. Jan 13, 2026AnnouncementShared information with investors. Filing
  19. Dec 1, 2025AgreementArmata Pharmaceuticals, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC with respect to an at the market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Armata Pharmaceuticals financials

Famous investors that hold ARMP

2 of the 50 well-known investors we track reported holding ARMP in their latest 13F filing. The largest position is Israel Englander's, worth $3.9M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20261.05M$3.9M0.0%+124%
Jim Simons · Renaissance TechnologiesQ3 202634,653$127K0.0%-28%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Armata Pharmaceuticals, Inc. (ARMP) stock

Who owns the most ARMP stock?

The largest reported owner of Armata Pharmaceuticals, Inc. (ARMP) is Madison Asset Management, LLC, with 5.8% of the company. In total, 54 funds and institutions reported holding ARMP at the end of Q2 2026, together about 14% of the shares. See the largest owners.

Are ARMP insiders buying or selling?

No ARMP insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ARMP?

As of Oct 30, 2026, 912,610 ARMP shares were sold short, 2.5% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 93,354 shares, buying them all back would take about 9.8 trading days (days to cover). See the history.

Which famous investors hold ARMP?

2 of the 50 well-known investors we track reported ARMP in their latest 13F filing, including Israel Englander, Jim Simons. The largest position is worth $3.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.